Anteris Technologies Global Corp. · NASDAQ:AVR
Anteris Technologies Global — PCR London Valves 2022
10 slides from Anteris Technologies Global's conference presentation, Nov 18, 2022
Slide 1: DurAVR TAVI novel leaflet design restores ascending aortic flow haemodynamics
DurAVR™ TAVI novel leaflet design restores ascending aortic flow haemodynamics on cardiac MRI: First-in-human study Pankaj Garg, MD University of East Anglia Norwich (UK)
Slide 2: Potential conflicts of interest
Potential conflicts of interest Speaker's name : Pankaj Garg ☑ I have the following potential conflicts of interest to declare: Receipt of grants / research support: Academy of Medical Science, MRC, NIHR, Wellcome Trust Receipt of honoraria or consultation fees: Anteris Technologies, NAMSA PCRLondon
Slide 3: Abnormal aortic flow may impact long-term cardiac performance
Abnormal aortic flow may impact long-term cardiac performance • Abnormal aortic flow is associated with loss of energy and makes the cardiovascular system less effective (PMID: 31535124) • Recent studies have shown that eccentric flow in aorta, measured by aortic flow displacement can predict aortic
Slide 4: Routine TAVR/SAVR alters ascending aortic blood flow
Routine TAVR/SAVR alters ascending aortic blood flow • TAVR results in increased wall shear stress in ascending aorta • TAVR/SAVR results in eccentric and displaced flow in the ascending aorta Farag et al. Eur Radiology (2019) 29:1444-1451 PCRLondonValves.com
Slide 5: DurAVR THV System
DurAVR™ THV System DurAVR™ THV System Single-piece aortic valve designed: To restore near-normal hemodynamic function For better coaptation and less leaflet stress Graphical representation of the 3D single-piece geometry of DurAVR™ THV (left), and standard balloon-expandable TAVI devices (right). Hy
Slide 6: Cardiac MRI study to assess aortic flow physiology
Cardiac MRI study to assess aortic flow physiology Objective: To investigate aortic flow physiology by cardiac MRI (cMRI) in 5 patients who received DurAVR™ transcatheter aortic valve (first-in-human) and compare results to normal age-height-weight matched controls, other transcutaneous AV implants
Slide 7: Aortic flow of healthy AV vs post-TAVR/SAVR: is there a difference?
Aortic flow of healthy AV vs post-TAVR/SAVR: is there a difference? Control Control Control Control DurAVR Other TAVIs SAVR vs other vs DurAVR vs SAVR TAVIs n=5 n=5 n=4 n=8 P-value P-value P-value Clinical characteristics Age (years) 60 ± 15 73 ± 9 77 ± 12 73 ± 9 0.115 0.102 0.064 Height (cm) 169 ±
Slide 8: DurAVR THV restores ascending aortic flow haemodynamics
DurAVR™ THV restores ascending aortic flow haemodynamics The novel leaflet design of DurAVR™ restores ascending aortic flow haemodynamics whereas SAVR and other TAVI valves do not demonstrate such physiological advantage PCRLondonValves.com
Slide 9: Why is this important?
Why is this important? • Restoration of normal laminal aortic flow is emerging as a novel target mainly to reduce energy loss in the cardiovascular system • Abnormal flow, including eccentric flow, is associated with continued aortic dilatation* which will further warrant intervention • As TAVI is b
Slide 10: PCRonline.com
PCR PCRonline.com